Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
- EligibilityCriteria: Inclusion Criteria:  14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD  Exclusion Criteria:  Age > 14 years. Patient weighing < 10 kg. History of severe Allergy History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke. Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past. Evidence or history of severe, moderate, or uncontrolled systemic disease. Inability to follow the prescribed dosing and follow-up schedule. Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period. Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study. History of premature birth <35 weeks' gestation. Prior history of stroke in utero or other in utero insult. - HealthyVolunteers: No - Gender: All - MinimumAge: 4 Years - MaximumAge: 14 Years - StdAgeList: Child